BRIDGEBIO PHARMA, INC.

Lobbying for BRIDGEBIO PHARMA, INC. · Biotech company

Filing · LD-2 quarterly report Q1 amendment

Reporting period

1st Quarter 2024

Jan 1 - Mar 31 · Posted Jul 17, 2026

Expenses

$160,000

What this organization spent lobbying with its own staff. The filing did not state which of the three LDA accounting methods produced this number, so it is not comparable with another filer's.

Client based in

California

Official filing document

Government bodies contacted

House of Representatives
Senate

Only the chambers were recorded for this filing. Any agencies it named are in the official document.

Lobbying activity 1

Pharmacy

Creating Hope Reauthorization Act of 2024 - H.R. 7384 Innovation in Pediatric Drugs Act - H.R. 6664 March-in/Bayh-Dole Act Orphan drug policies

Bills named in this filing 2

H.R. 7384
Creating Hope Reauthorization Act of 2024
H.R. 6664
Innovation in Pediatric Drugs Act of 2023

Source: federal Lobbying Disclosure Act filing, reproduced as filed. Bills are parsed from the activity descriptions.